Compounds · Metabolic & weight · Fat metabolism regulation and weight management
AOD9604 (hGH Fragment 176-191)
AOD-9604, AOD 9604, hGH Fragment 176-191, Tyr-hGH Fragment 177-191
Fragment of human growth hormone (amino acids 176–191) engineered in the 1990s to isolate hGH’s fat-burning action from its growth effects. Studied for fat loss and possibly joint/tissue repair; remains investigational with no approval.
0.3 mg daily, fasted
Research score 60/100. Reference only, not a prescription.
- Fat Loss
- Metabolic Enhancement
- Joint Support
- Recovery Enhancement
- Anti-inflammatory
- US status
- Research Chemical
- Approval
- Research Chemical Only
- Evidence
- Investigational for obesity and tissue repair. Clinical evidence is limited compared to approved metabolic drugs. No FDA approval.
- Research score
- 60 / 100
- Indication
- Research Only - No Medical Indication
- Origin
- Australia
- Source category
- Muscles & Joints
- Status group
- Research chemical
Mechanism
Mimics hGH’s lipid effects via β3-adrenergic receptor activation in fat tissue, raising cAMP/PKA signaling and hormone-sensitive lipase activity to break down triglycerides, without affecting glucose or IGF-1.
Safety file
Generally well tolerated; mild injection-site reactions, headache, nausea reported. Unlike hGH it doesn’t raise IGF-1 or cause insulin resistance, but WADA prohibits it.
- Injection site reactions
- Temporary fatigue
- Headache
Reconstitution
| Vial | 1 mL total | 2 mL total |
|---|---|---|
| 5 mg | 5 mg/mL | 2.5 mg/mL |
Reconstitutes with bacteriostatic water. If a vial stays cloudy, some dissolve it in a small amount of 0.6% acetic acid first (about 10 to 20% of the target volume), then top up with bac water; the acid counts toward the final volume.
- Add 0.6% acetic acid first, about 10 to 20% of your target volume (roughly 0.2 to 0.4 mL for a 2 mL fill), down the inside wall of the vial.
- Add bacteriostatic water slowly to reach your target volume (about 1.6 to 1.8 mL for a 2 mL fill), swirling as you go.
- Swirl gently until the solution is clear. Do not shake.
- If a vial has already gone cloudy in plain bac water, adding 0.6% acetic acid will usually clear it. If it stays cloudy after the acid, the peptide has aggregated and the vial should be discarded.
Protocol
Route: Subcutaneous
Standard protocol (subcutaneous)
- 0.3 mg (300 mcg) per day, injected fasted in the morning
- At a 2 mL fill on the 5 mg vial (2.5 mg/mL), 0.3 mg is a 0.12 mL draw (12 units)
Dosing detail
- Standard dose is 0.3 mg (300 mcg) daily, usually fasted in the morning.
- A modified GH fragment that targets fat metabolism without raising IGF-1 or overall GH, so it does not cause the water retention or growth effects of HGH.
- Daily consistency over a cycle is the approach.
- Well tolerated in human trials, but those trials did not show meaningful weight loss.
Duration
- Run several weeks to a few months, daily. Often paired with a GH secretagogue like Ipamorelin (AOD in the morning, Ipamorelin before bed).
Notes
- A fragment of GH studied for fat metabolism without the broader GH effects.
- Well tolerated in human trials, but those trials did not show meaningful weight loss.
- Inject subcutaneously and rotate sites.
Storage and handling
- Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
- Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
- Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
- If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.
- Cloudiness right after mixing usually means the wrong diluent, not a bad vial; reach for 0.6% acetic acid before writing it off. Cloudiness that appears days later in a previously clear vial is degradation, and that vial should be discarded.